

Results of Annual General Meeting

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") today held an Annual General Meeting of Members at the offices of BDO Australia - Melbourne, Collins Square, Tower 4/727 Collins St Docklands VIC 3008.

All resolutions were determined by a poll.

The outcome of each resolution put to shareholders at the Annual General Meeting is set out in the Annexure which accompanies this release.

Authority

This announcement has been authorised for release by the Company Secretary of Neurotech International Limited.

Investors:

Dr Thomas Duthy
Executive Director

td@neurotechinternational.com

+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company has commenced a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD and additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with Rett Syndrome during CY2023. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

Disclosure of Proxy Votes

Neurotech International Limited

Annual General Meeting

Wednesday, 15 November 2023



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 ADOPTION OF REMUNERATION REPORT	P	50,324,630	49,855,030 99.07%	296,000 0.59%	37,486,589	173,600 0.34%	50,028,630 99.41%	296,000 0.59%	37,486,589	Passed
2 RE-ELECTION OF DIRECTOR – MARK DAVIES	P	92,943,655	57,269,047 61.62%	675,000 0.73%	0	34,999,608 37.66%	94,268,655 99.29%	675,000 0.71%	0	Passed
3 APPROVAL OF 7.1A MANDATE	P	92,943,655	57,778,047 62.16%	166,000 0.18%	0	34,999,608 37.66%	94,777,655 99.83%	166,000 0.17%	0	Passed
4 REPLACEMENT OF CONSTITUTION	P	92,943,655	57,778,047 62.16%	166,000 0.18%	0	34,999,608 37.66%	94,777,655 99.83%	166,000 0.17%	0	Passed
5 RATIFICATION OF PRIOR ISSUE OF STOCKSDIGITAL SHARES	P	92,813,655	57,538,523 61.99%	275,524 0.30%	130,000	34,999,608 37.71%	94,538,131 99.71%	275,524 0.29%	130,000	Passed
6 APPROVAL TO ISSUE MERCHANT OPTIONS	P	92,913,655	57,538,523 61.93%	375,524 0.40%	30,000	34,999,608 37.67%	94,538,131 99.60%	375,524 0.40%	30,000	Passed

